Is this you? Create Your Porfile
Avatar

Scott Siegert

Neurocrine Biosciences

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Scott Siegert is active.

Explore More

Publication

Featured researches published by Scott Siegert.

Neurology | 2018

Short- and Long-term Effects of Once-Daily Valbenazine on Tardive Dyskinesia by Body Region (P4.079)

Cynthia L. Comella; Carlos Singer; Stephanie Lessig; Joshua Burke; Khodayar Farahmand; Sean Hinton; Grace S. Liang; Scott Siegert

Neurology | 2018

Estimation of an MCID for AIMS Total Score Change in Tardive Dyskinesia (P4.074)

Roger Kurlan; Mark Stacy; Khodayar Farahmand; Joshua Burke; Scott Siegert; Grace S. Liang

Neurology | 2018

Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078)

Stewart A. Factor; John Kane; Stephen R. Marder; Robert A. Hauser; Khodayar Farahmand; Roland Jimenez; Joshua Burke; Scott Siegert; Grace S. Liang

Cns Spectrums | 2018

150 Estimation of an MCID for AIMS Total Score Change in Tardive Dyskinesia

Martha Sajatovic; Andrew J. Cutler; Khodayar Farahmand; Joshua Burke; Scott Siegert; Grace S. Liang

Cns Spectrums | 2018

141 The Effects of Valbenazine on Tardive Dyskinesia: Subgroup Analyses of 3 Randomized, Double-Blind, Placebo-Controlled Trials

Jonathan M. Meyer; Gary Remington; Ali Norbash; Joshua Burke; Scott Siegert; Grace S. Liang

Cns Spectrums | 2018

132 Effects of Valbenazine on Depression and Suicidality in Adults With Tardive Dyskinesia: Pooled Results of 3 Double-Blind, Placebo-Controlled Trials

Gary Remington; Dao Thai-Cuarto; Joshua Burke; Scott Siegert; Grace S. Liang

American Journal of Geriatric Psychiatry | 2018

Long-Term Effects of Valbenazine on Tardive Dyskinesia in Older and Younger Adults

George S. Alexopoulos; Martha Sajatovic; Bijal Sheth; Scott Siegert; Khodayar Farahmand; Joshua Burke; Grace S. Liang

Schizophrenia Bulletin | 2017

M16. Valbenazine (nbi-98854) for the Treatment of Tardive Dyskinesia: Analysis by Underlying Psychiatric Diagnosis in Phase Iii Kinect 3 Study

Richard C. Josiassen; John M. Kane; Joshua Burke; Roland Jimenez; Scott Siegert; Grace S. Liang

Schizophrenia Bulletin | 2017

SA17. Response to Treatment With Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia

John M. Kane; Richard C. Josiassen; Joshua Burke; Roland Jimenez; Scott Siegert; Grace S. Liang

Neurology | 2016

Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27.001)

Mohammed Bari; Raj Shiwach; Roland Jimenez; Scott Siegert; Christopher O'Brien

Explore More

Collaboration

Dive into the Scott Siegert's collaboration.

Top Co-Authors
Avatar

Grace S. Liang

Neurocrine Biosciences

View shared research outputs
Top Co-Authors
Avatar

Joshua Burke

Neurocrine Biosciences

View shared research outputs
Top Co-Authors
Avatar

Khodayar Farahmand

Neurocrine Biosciences

View shared research outputs
Top Co-Authors
Avatar

Roland Jimenez

Neurocrine Biosciences

View shared research outputs
Top Co-Authors
Avatar

Christopher O'Brien

Neurocrine Biosciences

View shared research outputs
Top Co-Authors
Avatar

Egilius L. H. Spierings

Tufts University

View shared research outputs
Top Co-Authors
Avatar

John M. Kane

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors
Avatar

Martha Sajatovic

Case Western Reserve University

View shared research outputs
Top Co-Authors
Avatar

Peter McAllister

Yale University

View shared research outputs
Top Co-Authors
Avatar

Richard C. Josiassen

Drexel University

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge